PRESS RELEASE published on 07/08/2024 at 23:15, 1 year 8 months ago Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement Theralase® closes successful Non-Brokered Private Placement offering to fund cancer research and clinical studies. Proceeds to advance Phase II NMIBC study and Rutherrin® development Non-brokered Private Placement Theralase Technologies Inc. Cancer Research Rutherrin® Phase II NMIBC Study
BRIEF published on 06/20/2024 at 13:05, 1 year 9 months ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 1 year 9 months ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 1 year 9 months ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 1 year 9 months ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
BRIEF published on 06/19/2024 at 13:05, 1 year 9 months ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
PRESS RELEASE published on 06/19/2024 at 13:00, 1 year 9 months ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 1 year 9 months ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 1 year 9 months ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 1 year 9 months ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
Published on 04/01/2026 at 08:05, 1 hour 34 minutes ago Tocvan Discovers New Gold-Silver Zone 1,600 Meters From Main Zone at South Block Gran Pilar; First Aggressive Step-Out Drilling Intersects Mineralization From Surface
Published on 04/01/2026 at 08:00, 1 hour 39 minutes ago Caledonia Mining Corporation Plc - Notification of Relevant Change to Significant Shareholder
Published on 04/01/2026 at 04:06, 5 hours 33 minutes ago Jaguar Mining Reports Financial Results for the Fourth Quarter and Full Year 2025
Published on 04/01/2026 at 03:57, 5 hours 42 minutes ago NXT Energy Solutions Announces 2025 Year-End Results
Published on 04/01/2026 at 09:05, 34 minutes ago Solar Power to Go: Jackery Unveils SolarSaga 40 Air, the Next Generation of Compact Foldable Solar Panels
Published on 04/01/2026 at 09:05, 34 minutes ago Rockwell Automation Announces ROKStudios Video Series Launches a New Season Exploring the Journey from Automation to Autonomy
Published on 04/01/2026 at 09:00, 39 minutes ago Partners Group appoints Pete Zippelius as new Co-Head of Private Equity Health & Life
Published on 04/01/2026 at 08:00, 1 hour 39 minutes ago Transfert du contrat de liquidité aupres de Natixis Oddo BHF
Published on 04/01/2026 at 08:00, 1 hour 39 minutes ago Résultats annuels 2025 - ANR par action en hausse de + 8,1 % à 97,10 € - Fonds propres consolidés : 740 M€
Published on 03/31/2026 at 20:08, 13 hours 31 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 14 hours 34 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 14 hours 34 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
